Trial Profile
This retrospective study evaluating Bevacizumab (Avastin) treatment for severe pulmonary hypertension and high Cardiac output failure secondary to liver involvement in patients with hereditary hemorrhagic telangiectasia.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Nov 2017
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary)
- Indications Pulmonary hypertension
- Focus Therapeutic Use
- 17 Nov 2017 New trial record
- 24 Oct 2017 Results presented at The Liver Meeting 2017: 68th Annual Meeting of the American Association for the Study of Liver Diseases